BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15853160)

  • 1. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
    Láng I; Hitre E
    Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
    Samelis GF; Ekmektzoglou KA; Zografos GC
    Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
    Perez EA; Livingstone AS; Franceschi D; Rocha-Lima C; Lee DJ; Hodgson N; Jorda M; Koniaris LG
    J Am Coll Surg; 2006 Apr; 202(4):623-9. PubMed ID: 16571433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
    Papaetis GS; Syrigos KN
    Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
    Armbrust T; Sobotta M; Gunawan B; Füzesi L; Langer C; Cameron S; Ramadori G
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):819-23. PubMed ID: 19369884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors].
    Belev B; Vrbanec D; Kralik M; Plestina S; Petricević B; Sirotković-Skerlev M
    Acta Med Croatica; 2006 Dec; 60(5):471-5. PubMed ID: 17217104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
    Hohenberger P; Eisenberg B
    Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments.
    Reynoso D; Trent JC
    Curr Opin Oncol; 2010 Jul; 22(4):330-5. PubMed ID: 20520542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib in gastrointestinal stromal tumors.
    Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
    J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Strategy for patients with GIST after failure of imatinib].
    Abe S; Kubota T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):540-3. PubMed ID: 19381023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.